First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience

Authors

  • Ingrid Holst Olsen Department of Oncology 5073, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; Department of Surgery C 2122, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; Department of Clinical Physiology, Nuclear Medicine & PET 4011, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; Cluster for Molecular Imaging, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Seppo W. Langer Department of Oncology 5073, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Ida Jepsen European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Maria Assens European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Birgitte Federspiel Department of Pathology 5442, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Jane Preuss Hasselby Department of Pathology 5442, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Carsten Palnæs Hansen Department of Surgery C 2122, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Andreas Kjær Department of Clinical Physiology, Nuclear Medicine & PET 4011, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; Cluster for Molecular Imaging, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Ulrich Knigge Department of Surgery C 2122, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; Cluster for Molecular Imaging, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark

DOI:

https://doi.org/10.3109/0284186X.2011.582881

Abstract

Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer. Material and methods. We present the patient characteristics and treatment results of 31 consecutive, chemonaïve patients with PDECs treated with carboplatin, etoposide, and vincristine. Results. The response rate was 52%, the disease control rate 77%, and the median overall survival 15.3 months. The one-year survival rate was 55%, and the two-year survival rate was 19%. The median progression free survival (PFS) time was 6.6 months. Survival rates did not correlate with the Ki-67 proliferation index. The treatment was well tolerated. Conclusion. Treatment results with carboplatin, etoposide, and vincristine in chemonaïve patients with PDECs are comparable to those in patients with SCLC. The prognosis is however poor.

Downloads

Download data is not yet available.

Downloads

Published

2012-01-01

How to Cite

Holst Olsen, I., Langer, S. W., Jepsen, I., Assens, M., Federspiel, B., Preuss Hasselby, J., … Knigge, U. (2012). First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience. Acta Oncologica, 51(1), 97–100. https://doi.org/10.3109/0284186X.2011.582881

Issue

Vol. 51 No. 1 (2012): Acta Oncologica

Section

Articles